These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11078333)

  • 41. Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model.
    Battistini B; Verreault M; Ayach B; Blouin A; Cernacek P; Jeng AY; Wessale J; Opgenorth T; Tsang J
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S386-9. PubMed ID: 15838327
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065.
    Warner TD; Allcock GH; Vane JR
    Br J Pharmacol; 1994 May; 112(1):207-13. PubMed ID: 8032643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacologic characterization of S-1255, a highly potent and orally active endothelin A receptor antagonist.
    Iwasaki T; Mihara S; Shimamura T; Kawakami M; Masui M; Hayasaki-Kajiwara Y; Naya N; Ninomiya M; Fujimoto M; Nakajima M
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):471-82. PubMed ID: 11300660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats.
    Banfor PN; Franklin PA; Segreti JA; Widomski DL; Davidsen SK; Albert DH; Cox BF; Fryer RM; Gintant GA
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):173-8. PubMed ID: 19188829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes.
    Saleh MA; Boesen EI; Pollock JS; Savin VJ; Pollock DM
    Diabetologia; 2011 Apr; 54(4):979-88. PubMed ID: 21191784
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Direct determination of endothelin receptor antagonist levels in plasma using a scintillation proximity assay.
    Dayton BD; Chiou WJ; Opgenorth TJ; Wu-Wong JR
    Life Sci; 2000; 66(10):937-45. PubMed ID: 10714894
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the contractile effects and binding kinetics of endothelin-1 and sarafotoxin S6b in rat isolated renal artery.
    Devadason PS; Henry PJ
    Br J Pharmacol; 1997 May; 121(2):253-63. PubMed ID: 9154335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. LU 302 872 and its racemate (LU 224 332) show balanced endothelin-A/B receptor affinity, high oral activity, and inhibit human prostate tissue contractions.
    Raschack M; Göck S; Unger L; Hahn A; Amberg W; Jansen R; Alken P; Weber A; Hergenröder S
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S241-4. PubMed ID: 9595449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of ET(A) and ET(B) receptor blockade on post-ischemic cardiac dysfunction and norepinephrine overflow in isolated rat hearts.
    Yamamoto S; Matsumoto N; Kanazawa M; Fujita M; Takaoka M; Matsumura Y
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S394-7. PubMed ID: 15838330
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activation of the ET-1/ETA pathway contributes to erectile dysfunction associated with mineralocorticoid hypertension.
    Carneiro FS; Nunes KP; Giachini FR; Lima VV; Carneiro ZN; Nogueira EF; Leite R; Ergul A; Rainey WE; Clinton Webb R; Tostes RC
    J Sex Med; 2008 Dec; 5(12):2793-807. PubMed ID: 18823320
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity.
    von Geldern TW; Tasker AS; Sorensen BK; Winn M; Szczepankiewicz BG; Dixon DB; Chiou WJ; Wang L; Wessale JL; Adler A; Marsh KC; Nguyen B; Opgenorth TJ
    J Med Chem; 1999 Sep; 42(18):3668-78. PubMed ID: 10479298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.
    Thakkar SG; Choueiri TK; Garcia JA
    Curr Oncol Rep; 2006 Mar; 8(2):108-13. PubMed ID: 16507220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endothelin-1-induced contraction of pulmonary arteries from endotoxemic rats is attenuated by the endothelin-A receptor antagonist, BQ123.
    Curzen NP; Mitchell JA; Jourdan KB; Griffiths MJ; Evans TW
    Crit Care Med; 1996 Dec; 24(12):2007-13. PubMed ID: 8968269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.
    Jin C; Jeon Y; Kleven DT; Pollock JS; White JJ; Pollock DM
    J Pharmacol Exp Ther; 2014 Nov; 351(2):467-73. PubMed ID: 25189702
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats.
    Vanêcková I; Kramer HJ; Bäcker A; Vernerová Z; Opocensky M; Cervenka L
    Hypertension; 2005 Oct; 46(4):969-74. PubMed ID: 16157796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of a novel bifunctional endothelin receptor antagonist, IRL 3630A, on guinea pig respiratory mechanics.
    Makatani M; Fujitani Y; Takimoto M; Oda K; Sasaki Y; Hori S; Inui T; Sakaki J; Okada T; Hoshiko K; Yamamura T
    Eur J Pharmacol; 2000 Oct; 406(1):139-47. PubMed ID: 11011045
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of A-192621.1, a specific endothelin-B antagonist, on intrarenal hemodynamic responses to endothelin-1.
    Brodsky S; Abassi Z; Wessale J; Ramadan R; Winaver J; Hoffman A
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S311-3. PubMed ID: 11078406
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiac microvasculature in DOCA-salt hypertensive rats : effect of endothelin ET(A) receptor antagonism.
    Larouche I; Schiffrin EL
    Hypertension; 1999 Oct; 34(4 Pt 2):795-801. PubMed ID: 10523363
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist.
    Williams DL; Murphy KL; Nolan NA; O'Brien JA; Pettibone DJ; Kivlighn SD; Krause SM; Lis EV; Zingaro GJ; Gabel RA
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1518-26. PubMed ID: 8531124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist.
    Hoshino T; Yamauchi R; Kikkawa K; Yabana H; Murata S
    J Pharmacol Exp Ther; 1998 Aug; 286(2):643-9. PubMed ID: 9694915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.